| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/28/2022 | 98.02% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 08/16/2022 | 32.01% | SVB Leerink | $9 → $4 | Maintains | Outperform |
| 07/11/2022 | 197.03% | SVB Leerink | $13 → $9 | Maintains | Outperform |
| 04/26/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 04/26/2022 | 329.04% | SVB Leerink | $33 → $13 | Maintains | Outperform |
| 09/07/2021 | 956.11% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 09/07/2021 | 1055.12% | Stifel | → $35 | Initiates Coverage On | → Buy |
| 09/07/2021 | 989.11% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
Eliem Therapeutics Questions & Answers
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on October 28, 2022. The analyst firm set a price target for $6.00 expecting ELYM to rise to within 12 months (a possible 98.02% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on October 28, 2022 so you should expect the next rating to be made available sometime around October 28, 2023.
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a initiated with a price target of $0.00 to $6.00. The current price Eliem Therapeutics (ELYM) is trading at is $3.03, which is within the analyst's predicted range.